WASHINGTON, D.C. (Tuesday, May 04, 2011) - The Biotechnology Industry Organization (BIO) announced today its selection of Representative David E. Price (D-NC) as Legislator of the Year for 2010-2011. Congressman Price will receive the award during the BIO Legislative Day Fly-In today.
“Biotechnology is the ‘good jobs’ industry of the 21st Century. It has helped transform the Research Triangle area of North Carolina, which I am proud to represent, into one of the best places in the country to live, work, start a business and raise a family. Our nation’s long-term economic competitiveness depends on continued investments in innovative industries like biotechnology,” said Congressman Price.
“As an early cosponsor of the Pathway for Biosimilars Act and a champion of its inclusion in the Affordable Care Act in 2010, Congressman Price helped ensure that the biotechnology industry can remain vibrant and research-intensive while remaining dedicated to providing life-enhancing and life-saving therapies to patients,” said BIO President and CEO Jim Greenwood.
“Furthermore, his past work as Chairman of the Appropriations Subcommittee on Homeland Security ensured funding to incentivize the development of therapies intended for use in the event of a bioterrorist event.” “Congressman Price represents one of the most biotech-intensive Congressional districts in the United States, and has been an invaluable resource for the biotechnology community – both in the 4th District and North Carolina at large,” said Sam Taylor, President of the North Carolina Biosciences Organization.
“His leadership on numerous issues of importance to the industry and commitment to understanding the needs of America’s biotechnology sector should be a model for all his colleagues in the Congress. On behalf of the North Carolina biotechnology life science industry, NCBIO congratulates Congressman Price on receiving this award.”
More than 200 biotechnology industry representatives from 36 states will participate in hundreds of meetings with Members of the House and Senate during the BIO Legislative Day Fly-In. Participants will discuss issues critical to the biotechnology industry including patent reform, increased funding for the Food and Drug Administration and National Institutes of Health, restored eligibility for Small Business Innovation Research grants, and extension of the Therapeutic Discovery Project Program.
Photos of the award presentation are available upon request.